Search Results - "Cruess, Alan F."

The cost of vision loss in Canada. 2. Results by Cruess, Alan F., MD, FRCSC, Gordon, Keith D., PhD, Bellan, Lorne, MD, FRCSC, Mitchell, Scott, BEc, Pezzullo, M. Lynne, BEc

“…Abstract Objective This study was conducted to provide the financial underpinnings necessary for effective planning for the provision of eye health services in…”
Get full text

VEGF-A is increased in exogenous endophthalmitis by Seamone, Mark E., MSc, MD, Lewis, Darrell R., MD, Haidl, Ian D., PhD, Gupta, R. Rishi, MD, O’ Brien, Daniel M., MD, Dickinson, John, MD, Samad, Arif, MD, Marshall, Jean S., PhD, Cruess, Alan F., MD

“…Abstract Objective Exogenous endophthalmitis is an ophthalmologic emergency defined by panocular inflammation. Vascular endothelial growth factor A (VEGF-A)…”
Get full text

Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration by Kaiser, Peter K., MD, Boyer, David S., MD, Cruess, Alan F., MD, Slakter, Jason S., MD, Pilz, Stefan, PhD, Weisberger, Annemarie, MD

“…Purpose To demonstrate noninferiority of ranibizumab in combination with verteporfin photodynamic therapy (PDT) versus ranibizumab monotherapy in patients with…”
Get full text

Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME by Berger, Alan, MD, Sheidow, Tom, MD, Cruess, Alan F., MD, Arbour, Jean Daniel, MD, Courseau, Anne-Sophie, PharmD, de Takacsy, Frederica, BSc

“…Abstract Objective To compare the efficacy and safety of ranibizumab 0.5 mg intravitreal injection, as monotherapy or in combination with laser, with laser…”
Get full text

Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration by Cruess, Alan F., MD, Berger, Alan, MD, Colleaux, Kevin, MD, Greve, Mark, MD, Harvey, Patricia, MD, Kertes, Peter J., MD, Sheidow, Thomas, MD, Tourville, Eric, MD, Williams, Geoff, MD, Wong, David, MD

“…Abstract Background New therapeutic approaches, particularly anti-vascular endothelial growth factor (anti-VEGF) therapies, prevent, and in some cases reverse,…”
Get full text

Verteporfın plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration: Twelve-Month Results of the DENALI Study by KAISER, Peter K, BOYER, David S, CRUESS, Alan F, SLAKTER, Jason S, PILZ, Stefan, WEISBERGER, Annemarie

“…To demonstrate noninferiority of ranibizumab in combination with verteporfin photodynamic therapy (PDT) versus ranibizumab monotherapy in patients with…”
Get full text

Predictors of visual outcomes in patients with neovascular age‐related macular degeneration treated with anti‐vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies by Lanzetta, Paolo, Cruess, Alan F., Cohen, Salomon Y., Slakter, Jason S., Katz, Todd, Sowade, Olaf, Zeitz, Oliver, Ahlers, Christiane, Mitchell, Paul

“…Purpose Identify predictors for response to anti‐vascular endothelial growth factor (VEGF) therapy in patients with neovascular (wet) age‐related macular…”
Get full text

The cost of vision loss in Canada. 1. Methodology by Gordon, Keith D., PhD, Cruess, Alan F., MD, FRCSC, Bellan, Lorne, MD, FRCSC, Mitchell, Scott, BEc, Pezzullo, M. Lynne, BEc

“…Abstract Objective This paper outlines the methodology used to estimate the cost of vision loss in Canada. The results of this study will be presented in a…”
Get full text

Photodynamic therapy with verteporfin in age‐related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties by Cruess, Alan F., Zlateva, Gergana, Pleil, Andreas M., Wirostko, Barbara

“… Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age‐related macular degeneration (AMD), and…”
Get full text

Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad by Croft, Daniel E, Wykoff, Charles C, Michels, Stephan, Chakravarthy, Usha, Cruess, Alan F

“…Phase III Clinical Trials: Assessing Safety and Efficacy Regulatory bodies around the world, including the Food and Drug Administration (FDA), the European…”
Get full text

Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration by Cruess, Alan F, Giacomantonio, Nicholas

“…Emerging safety data, accompanied with recent demographic trends, point to the need for an in-depth review and consideration of potential consequences that…”
Get more information

Use of fluorescein and indocyanine green angiography in polypoidal choroidal vasculopathy patients following photodynamic therapy by Windisch, Roman, MD, FEBO, Windisch, Bettina K., MD, FEBO, Cruess, Alan F., MD, FRCSC

“…Abstract Background: Exudative age-related macular degeneration (AMD) is a sight-threatening event in many elderly people. Some patients have a much better…”
Get full text

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus by Berger, Alan R, Cruess, Alan F, Altomare, Filiberto, Chaudhary, Varun, Colleaux, Kevin, Greve, Mark, Kherani, Amin, Mandelcorn, Efrem D, Parsons, Hugh, Rhéaume, Marc-André, Tourville, Eric

“…The availability of new therapeutic approaches, particularly intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies, has prompted…”
Get more information

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines by Kaiser, Peter K., Cruess, Alan F., Bogaert, Peter, Khunti, Kamlesh, Kelly, Simon P.

“…Vascular endothelial growth factor (VEGF) inhibitor medications such as ranibizumab, pegaptanib and bevacizumab are in use for the treatment of neovascular…”
Get full text

What percentage of patients presenting for routine eye examinations require referral for secondary care? A study of referrals from optometrists to ophthalmologists by Dobbelsteyn, David, Mckee, Katherine, Bearnes, Reece D, Jayanetti, Sujani N, Persaud, David D, Cruess, Alan F

“…The aim was to investigate the percentage of asymptomatic patients presenting for routine optometric eye examinations that have pathology or pathology-related…”
Get full text

Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study by Cruess, Alan F., Zlateva, Gergana, Xu, Xiao, Soubrane, Gièle, Pauleikhoff, Daniel, Lotery, Andrew, Mones, Jordi, Buggage, Ronald, Schaefer, Caroline, Knight, Tyler, Goss, Thomas F.

“…Background There is limited previous research examining the healthcare costs of neovascular age-related macular degeneration (NV-AMD), which constrains our…”
Get full text

The Letter Contrast Sensitivity Test: Clinical Evaluation of a New Design by Haymes, Sharon A, Roberts, Kenneth F, Cruess, Alan F, Nicolela, Marcelo T, LeBlanc, Raymond P, Ramsey, Michael S, Chauhan, Balwantray C, Artes, Paul H

“…To compare the reliability, validity, and responsiveness of the Mars Letter Contrast Sensitivity (CS) Test to the Pelli-Robson CS Chart. One eye of 47 normal…”
Get full text

Reliability of the time trade-off technique of utility assessment in patients with retinal disease by Hollands, Hussein, MSc, Lam, Miu, PhD, Pater, Joe, MD, MSc, Albiani, Dave, BSc, Brown, Gary C., MD, MBA, Brown, Melissa, MD, MBA, Cruess, Alan F., MD, Sharma, Sanjay, MD, MSc

“…Abstract Background: Studies in medical fields other than ophthalmology have given conflicting results regarding the reliability of the time trade-off…”
Get full text

Choroidal neovascularization with interferon associated retinopathy: case report and review of literature by Bazarah, Salem M, Ritenour, Rusty, Patel, Sunil T, Hirsch, Geri, Peltekian, Kevork M, Cruess, Alan F

“…We report a case of new interferon-associated ocular complication during treatment with combination of pegylated interferon plus ribavirin for chronic…”
Get full text

Erratum to: Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines by Kaiser, Peter K., Cruess, Alan F., Bogaert, Peter, Khunti, Kamlesh, Kelly, Simon P.

Get full text